Literature DB >> 11437993

CXCR3 expression in human central nervous system diseases.

S H Goldberg1, P van der Meer, J Hesselgesser, S Jaffer, D L Kolson, A V Albright, F González-Scarano, E Lavi.   

Abstract

The CXCR3 chemokine receptor, expressed on activated T lymphocytes, is seen within the central nervous system (CNS) in inflammatory conditions where a T-cell response is prominent. However, the distribution of CXCR3 in parenchymal CNS cells is unknown. Using a monoclonal antibody against CXCR3 and post-mortem tissue of patients with and without CNS pathology, we have determined its expression pattern. CXCR3 was found in subpopulations of cells morphologically consistent with astrocytes, particularly reactive astrocytes, and in cerebellar Purkinje cells. It was also detected in arterial endothelial and smooth muscle cells, particularly in areas associated with atherosclerotic plaques. CXCR3-positive astrocytes were particularly prominent in the CNS of HIV-positive patients, in patients with Multiple Sclerosis (MS), in ischaemic infarcts and in astrocytic neoplasms. Immunofluorescence studies of mixed adult primary glial cultures and fetal glial cultures also showed expression of CXCR3 in astrocytes. CXCR3 mRNA was detected in Purkinje cells by in situ hybridization with a CXCR3-specific probe. Thus, the predominant expression of CXCR3 in reactive astrocytes may indicate that it plays a role in the development of reactive gliosis in a variety of infectious, inflammatory, vascular and neoplastic processes in the CNS. The relationship between CXCR3 expression in astrocytes to its expression in Purkinje cells, endothelial cells and smooth muscle cells is yet to be determined.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11437993     DOI: 10.1046/j.1365-2990.2001.00312.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  28 in total

Review 1.  CXC chemokine receptors in the central nervous system: Role in cerebellar neuromodulation and development.

Authors:  Davide Ragozzino
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 2.  Neuronal chemokines: versatile messengers in central nervous system cell interaction.

Authors:  A H de Haas; H R J van Weering; E K de Jong; H W G M Boddeke; K P H Biber
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

3.  Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1.

Authors:  Kakuri M Omari; Sarah E Lutz; Laura Santambrogio; Sergio A Lira; Cedric S Raine
Journal:  Am J Pathol       Date:  2008-12-18       Impact factor: 4.307

4.  Lipocalin-2 Is a chemokine inducer in the central nervous system: role of chemokine ligand 10 (CXCL10) in lipocalin-2-induced cell migration.

Authors:  Shinrye Lee; Jong-Heon Kim; Jae-Hong Kim; Jung-Wan Seo; Hyung-Soo Han; Won-Ha Lee; Kiyoshi Mori; Kazuwa Nakao; Jonathan Barasch; Kyoungho Suk
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

5.  TNF-alpha-dependent regulation of CXCR3 expression modulates neuronal survival during West Nile virus encephalitis.

Authors:  Bo Zhang; Jigisha Patel; Michelle Croyle; Michael S Diamond; Robyn S Klein
Journal:  J Neuroimmunol       Date:  2010-06-25       Impact factor: 3.478

6.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3.

Authors:  Dianhua Jiang; Jiurong Liang; Jennifer Hodge; Bao Lu; Zhou Zhu; Shuang Yu; Juan Fan; Yunfei Gao; Zhinan Yin; Robert Homer; Craig Gerard; Paul W Noble
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 7.  CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus.

Authors:  Zahra Ahmadi; Mohammad Kazemi Arababadi; Gholamhossin Hassanshahi
Journal:  Inflammation       Date:  2013-04       Impact factor: 4.092

Review 8.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

9.  Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.

Authors:  M R Pranzatelli; E D Tate; N R McGee; A L Travelstead; S J Verhulst; R M Ransohoff
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

10.  Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice.

Authors:  Rui-Sheng Duan; Xin Yang; Zhi-Guo Chen; Ming-Ou Lu; Chris Morris; Bengt Winblad; Jie Zhu
Journal:  Neurochem Res       Date:  2007-12-20       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.